Search research articles
Contact Us
Filters
Showing results (181-190 of 367) with videos related to
Page
of 37
Sort By:
Archives of Pathology & Laboratory Medicine
|
September 19, 2024
Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies
Zhenhao Qi, Thomas Ha, Wenqin Feng, et al.
The Journal of Nutrition
|
August 27, 2010
Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment
Barbara S van der Meij, Jacqueline A E Langius, Egbert F Smit, et al.
Virchows Archiv : an International Journal of Pathology
|
October 31, 2006
Diminished expression of multidrug resistance-associated protein 1 (MRP1) in bronchial epithelium of COPD patients
Margaretha van der Deen, Hendrik Marks, Brigitte W M Willemse, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 18, 2014
Parametric methods for quantification of 18F-FAZA kinetics in non-small cell lung cancer patients
Eline E Verwer, Idris Bahce, Floris H P van Velden, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 28, 2016
Accuracy and Precision of Partial-Volume Correction in Oncological PET/CT Studies
Matthijs C F Cysouw, Gerbrand Maria Kramer, Otto S Hoekstra, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 8, 2017
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib
Leora Horn, Scott Gettinger, D Ross Camidge, et al.
The Journal of Molecular Diagnostics : JMD
|
January 29, 2025
Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non-Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02
Zhenhao Qi, Shinya Tokuhiro, Justin I Odegaard, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 12, 2010
Comprehensive CADM1 promoter methylation analysis in NSCLC and normal lung specimens
Remco M van den Berg, Peter J F Snijders, Katrien Grünberg, et al.
Oncoimmunology
|
July 4, 2015
Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer
Pauline L de Goeje, Koen Bezemer, Marlies E Heuvers, et al.
Nuclear Medicine and Biology
|
July 29, 2014
Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors
Paul Slobbe, Albert D Windhorst, Marijke Stigter-van Walsum, et al.
Page
of 37
Search research articles
Search
Showing results (181-190 of 367) with videos related to
Sort By:
Page
of 37
Archives of Pathology & Laboratory Medicine
|
September 19, 2024
Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies
Zhenhao Qi, Thomas Ha, Wenqin Feng, et al.
The Journal of Nutrition
|
August 27, 2010
Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment
Barbara S van der Meij, Jacqueline A E Langius, Egbert F Smit, et al.
Virchows Archiv : an International Journal of Pathology
|
October 31, 2006
Diminished expression of multidrug resistance-associated protein 1 (MRP1) in bronchial epithelium of COPD patients
Margaretha van der Deen, Hendrik Marks, Brigitte W M Willemse, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 18, 2014
Parametric methods for quantification of 18F-FAZA kinetics in non-small cell lung cancer patients
Eline E Verwer, Idris Bahce, Floris H P van Velden, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 28, 2016
Accuracy and Precision of Partial-Volume Correction in Oncological PET/CT Studies
Matthijs C F Cysouw, Gerbrand Maria Kramer, Otto S Hoekstra, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 8, 2017
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib
Leora Horn, Scott Gettinger, D Ross Camidge, et al.
The Journal of Molecular Diagnostics : JMD
|
January 29, 2025
Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non-Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02
Zhenhao Qi, Shinya Tokuhiro, Justin I Odegaard, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 12, 2010
Comprehensive CADM1 promoter methylation analysis in NSCLC and normal lung specimens
Remco M van den Berg, Peter J F Snijders, Katrien Grünberg, et al.
Oncoimmunology
|
July 4, 2015
Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer
Pauline L de Goeje, Koen Bezemer, Marlies E Heuvers, et al.
Nuclear Medicine and Biology
|
July 29, 2014
Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors
Paul Slobbe, Albert D Windhorst, Marijke Stigter-van Walsum, et al.
Page
of 37